Cancer biotech Chimeric soars 50pc on debut
Cancer biotech Chimeric soars 50pc on debut “We have a bit of a history with [Chimeric executive chairman] Paul Hopper,” he said. “We were the largest institution in Viralytics [Mr Hopper’s previous venture] and when it was sold we owned about 10 per cent and we were happy with that outcome. “We think Paul has […]
Read More